Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''

  • Galit Driban
  • , Amit Assa

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)2501
Number of pages1
JournalDigestive and Liver Disease
Volume57
Issue number12
DOIs
StatePublished - 1 Dec 2025
Externally publishedYes

Keywords

  • Response to letter to the editor

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this